BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 23124440)

  • 21. Evaluation of novel cell cycle inhibitors in mantle cell lymphoma.
    Park IW; Reddy MV; Reddy EP; Groopman JE
    Oncogene; 2007 Aug; 26(38):5635-42. PubMed ID: 17369860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
    Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
    Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma.
    Haritunians T; Mori A; O'Kelly J; Luong QT; Giles FJ; Koeffler HP
    Leukemia; 2007 Feb; 21(2):333-9. PubMed ID: 17136116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Arsenic trioxide rewires mantle cell lymphoma response to bortezomib.
    Zhao LL; Liu YF; Peng LJ; Fei AM; Cui W; Miao SC; Hermine O; Gressin R; Khochbin S; Chen SJ; Wang J; Mi JQ
    Cancer Med; 2015 Nov; 4(11):1754-66. PubMed ID: 26310857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma.
    Alas S; Ng CP; Bonavida B
    Clin Cancer Res; 2002 Mar; 8(3):836-45. PubMed ID: 11895917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-multiple lymphomatous polyposis form of mantle cell lymphoma in the gastrointestinal tract.
    Tamura S; Ohkawauchi K; Yokoyama Y; Higashidani Y; Daibata M; Hiroi M; Yamamori S; Onishi S
    J Gastroenterol; 2004 Oct; 39(10):995-1000. PubMed ID: 15549454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
    Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
    Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
    Dawar R; Hernandez-Ilizaliturri F
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.
    Czuczman NM; Barth MJ; Gu J; Neppalli V; Mavis C; Frys SE; Hu Q; Liu S; Klener P; Vockova P; Czuczman MS; Hernandez-Ilizaliturri FJ
    Blood; 2016 Mar; 127(9):1128-37. PubMed ID: 26675347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
    Kanaji N; Ishibashi K; Uno H; Hino N
    Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Disappearance of CD 20 after treatment with rituximab of mantle cell lymphoma].
    Yoshida K; Kayano H; Shimada T; Wakao D; Takahashi N; Sugahara Y; Yagasaki F; Ito Y; Kawai N; Matsuda A; Suzuki T; Bessho M
    Rinsho Ketsueki; 2003 Mar; 44(3):174-81. PubMed ID: 12722344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
    Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
    J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNFalpha/NF-kappaB signaling axis.
    Zak Z; Gelebart P; Lai R
    Leukemia; 2010 Aug; 24(8):1476-86. PubMed ID: 20520642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo.
    Qian Z; Zhang L; Cai Z; Sun L; Wang H; Yi Q; Wang M
    Leuk Res; 2011 Mar; 35(3):380-6. PubMed ID: 21047686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
    Shirsath NP; Manohar SM; Joshi KS
    Mol Cancer; 2012 Oct; 11():77. PubMed ID: 23075291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mantle cell lymphoma in the ocular adnexal region.
    Looi A; Gascoyne RD; Chhanabhai M; Connors JM; Rootman J; White VA
    Ophthalmology; 2005 Jan; 112(1):114-9. PubMed ID: 15629830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.
    Alinari L; Prince CJ; Edwards RB; Towns WH; Mani R; Lehman A; Zhang X; Jarjoura D; Pan L; Kinghorn AD; Grever MR; Baiocchi RA; Lucas DM
    Clin Cancer Res; 2012 Sep; 18(17):4600-11. PubMed ID: 22791882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma.
    Beltran E; Fresquet V; Martinez-Useros J; Richter-Larrea JA; Sagardoy A; Sesma I; Almada LL; Montes-Moreno S; Siebert R; Gesk S; Calasanz MJ; Malumbres R; Rieger M; Prosper F; Lossos IS; Piris MA; Fernandez-Zapico ME; Martinez-Climent JA
    Proc Natl Acad Sci U S A; 2011 Jul; 108(30):12461-6. PubMed ID: 21746927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
    Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.